Article

Targeting Staufen 1 with antisense oligonucleotides for treating ALS and SCA2

2022-11-17

Abstract excerpt

<h4>ABSTRACT</h4> Staufen1 (STAU1) is a multifunctional RNA binding protein that controls mRNA degradation and subcellular localization. STAU1 interacts with the ATXN2 protein, that is polyglutamine expanded in spinocerebellar ataxia type 2 (SCA2). We previously showed that STAU1 is elevated and aggregated in cells from SCA2 patients, cells from amyotrophic lateral sclerosis (ALS) patients, and in SCA2 and ALS mo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8f35682f-492f-5ca3-a871-776328e44be0
DOI: 10.1101/2022.11.16.516816

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting Staufen 1 with antisense oligonucleotides for treating ALS and SCA2DOI 10.1101/2022.11.16.516816Read

A human Staufen1 BAC transgenic mouse exhibits abnormal autophagy and neurodegeneration across the central nervous systemSemantic proximity Read

Staufen1 links RNA stress granules and autophagy in a model of neurodegenerationSemantic proximity Read

Oligonucleotide therapeutics in neurodegenerative diseasesSemantic proximity Read

Small molecule v-ATPase inhibitor Etidronate lowers levels of ALS protein ataxin-2Semantic proximity Read

Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and ShadeSemantic proximity Read

Antisense oligonucleotides (ASOs) in motor neuron diseases: a road to cure in light and shadeSemantic proximity Read

Staufen1 in Human NeurodegenerationSemantic proximity Read

Antisense therapies in neurological diseasesSemantic proximity Read

AAV-based delivery of RNAi targeting Ataxin-2 improves survival, strength, and pathology in mouse models of rapidly and slowly progressive sporadic ALSSemantic proximity Read

<i>HnRNPAB</i> -targeted antisense oligonucleotides ameliorate tau pathology and cognitive deficits by modulating Alzheimer’s disease-associated alternative splicingSemantic proximity Read

Antisense oligonucleotide therapy for spinocerebellar ataxia type 2.Semantic proximity Read

U7 small nuclear RNA splice-switching therapeutics for STMN2 and UNC13A in Amyotrophic Lateral SclerosisSemantic proximity Read